Laman UtamaSGEN • BMV
add
Seagen
Tutup sebelumnya
$3,711.48
Julat tahun
$3,711.48 - $3,711.48
Permodalan pasaran
43.15B USD
Nisbah P/E
-
Hasil dividen
-
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD) | Sep 2023info | Perubahan T/T |
---|---|---|
Hasil | 648.65J | 27.11% |
Perbelanjaan pengendalian | 262.69J | 24.86% |
Pendapatan bersih | -215.79J | -13.09% |
Margin untung bersih | -33.27 | 11.02% |
Pendapatan bagi setiap syer | -1.15 | -11.65% |
EBITDA | -209.33J | -19.47% |
Kadar cukai berkesan | 0.26% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(USD) | Sep 2023info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 1.24B | -29.86% |
Jumlah aset | 3.63B | 0.42% |
Jumlah liabiliti | 1.08B | 35.94% |
Jumlah ekuiti | 2.55B | — |
Syer tertunggak | 188.66J | — |
Harga kepada buku | 274.52 | — |
Pulangan pada aset | -16.01% | — |
Pulangan pada modal | -21.12% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(USD) | Sep 2023info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -215.79J | -13.09% |
Tunai daripada operasi | -35.82J | 58.21% |
Tunai daripada pelaburan | 142.49J | 119.31% |
Tunai daripada pembiayaan | 15.52J | -15.59% |
Perubahan bersih dalam tunai | 119.90J | 1,958.05% |
Aliran tunai bebas | 71.52J | 1,141.10% |
Perihal
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Diasaskan
15 Jul 1997
Ibu pejabat
Tapak web
Pekerja
3,256